Key result
Nebivolol 5 mg daily for 6 months significantly reduced total antioxidant capacity (from 501 to 422 trolox equivalent, P<0.001) and increased atherogenic LDL subfractions in type 2 diabetics.
Why the study?
Does nebivolol 5 mg daily improve glycaemic control, lipid profile, and oxidative stress in patients with type 2 diabetes and mild to moderate hypertension?
Population
26 patients with type 2 diabetes and mild to moderate hypertension
Design
Cohort
Follow-up
6 months
Authors
Loading...
Nebivolol may promote atherogenic LDL and reduce antioxidant capacity in T2DM; hypothesis-generating and should not yet change practice.
Does nebivolol 5 mg daily improve glycaemic control, lipid profile, and oxidative stress in patients with type 2 diabetes and mild to moderate hypertension?
Absolute Event Rate: 422% vs 501%
p-value: p=<0.001
In patients with type 2 diabetes and hypertension, nebivolol treatment may promote a more atherogenic LDL profile and reduce antioxidant defenses, despite a positive effect on HDL cholesterol.
Peter et al. (2006) studied Type 2 diabetes with mild to moderate hypertension (n=26). Nebivolol vs. Baseline was evaluated on Total antioxidant capacity (TAC) (p=<0.001). Nebivolol 5 mg daily for 6 months significantly reduced total antioxidant capacity (from 501 to 422 trolox equivalent, P<0.001) and increased atherogenic LDL subfractions in type 2 diabetics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: